Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Upgraded by StockNews.com to Strong-Buy

StockNews.com upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a buy rating to a strong-buy rating in a report published on Wednesday.

FMS has been the topic of a number of other reports. Morgan Stanley boosted their target price on shares of Fresenius Medical Care AG & Co. KGaA to €40.50 ($43.55) in a report on Wednesday, August 16th. Truist Financial boosted their target price on shares of Fresenius Medical Care AG & Co. KGaA from $26.00 to $28.00 and gave the stock a hold rating in a report on Thursday, July 13th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a buy rating to a neutral rating in a report on Monday, August 14th. The Goldman Sachs Group began coverage on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, July 12th. They issued a buy rating on the stock. Finally, Citigroup began coverage on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 1st. They issued a neutral rating on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has a consensus rating of Hold and an average price target of $29.89.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE FMS opened at $22.40 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.91 and a current ratio of 1.26. The company has a market cap of $13.14 billion, a P/E ratio of 21.33 and a beta of 1.06. The firm’s fifty day moving average is $24.72 and its two-hundred day moving average is $23.08. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $12.78 and a 52-week high of $27.72.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.19 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.01% and a return on equity of 5.15%. As a group, analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently made changes to their positions in FMS. Raymond James & Associates boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 35.6% during the 1st quarter. Raymond James & Associates now owns 28,440 shares of the company’s stock worth $958,000 after purchasing an additional 7,470 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in Fresenius Medical Care AG & Co. KGaA by 13.0% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 9,490 shares of the company’s stock valued at $320,000 after buying an additional 1,089 shares during the period. Bank of New York Mellon Corp grew its stake in Fresenius Medical Care AG & Co. KGaA by 17.4% in the 1st quarter. Bank of New York Mellon Corp now owns 28,037 shares of the company’s stock worth $945,000 after acquiring an additional 4,162 shares in the last quarter. American Century Companies Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 15.0% in the 1st quarter. American Century Companies Inc. now owns 9,477 shares of the company’s stock worth $319,000 after acquiring an additional 1,238 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 56.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 29,668 shares of the company’s stock worth $1,000,000 after acquiring an additional 10,676 shares in the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.